13 studies were found.

1.		No longer recruiting	Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy Conditions: stage IV prostate cancer; recurrent prostate cancer
2.		No longer recruiting	BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Conditions: adult solid tumor; Breast Cancer; Endocrine Cancer; female reproductive cancer
3.		No longer recruiting	Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Conditions: Lymphocytic Lymphoma; Hodgkin's Disease; Non-Hodgkin's Lymphoma
4.		Completed	Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors Condition: unspecified adult solid tumor, protocol specific
5.		No longer recruiting	Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Conditions: Pancreatic Cancer; Gastric Cancer; adult primary liver cancer
6.		No longer recruiting	Docetaxel and GEM 231 in Treating Patients with Recurrent or Refractory Solid Tumors Condition: unspecified adult solid tumor, protocol specific
7.		No longer recruiting	Irinotecan and Capecitabine in Treating Patients With Solid Tumors Conditions: Pancreatic Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; adult primary liver cancer; Colon Cancer; Rectal Cancer; Breast Cancer
8.		Not yet recruiting	Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Conditions: stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent ovarian epithelial cancer; peritoneal cavity cancer
9.		Suspended	Paclitaxel and Bryostatin-1 in Treating Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Conditions: stage II pancreatic cancer; stage III pancreatic cancer; recurrent pancreatic cancer; adenocarcinoma of the pancreas; stage IVA pancreatic cancer; ...
10.		No longer recruiting	Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors Condition: unspecified adult solid tumor, protocol specific
11.		Completed	Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
12.		Recruiting	Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Conditions: inflammatory breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer
13.		No longer recruiting	Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma Conditions: Stage IV Melanoma; stage III melanoma; Recurrent Melanoma